Cyprotex beat
Drug testing specialist Cyprotex (CRX:AIM) shoots 9.1% higher to 71.5p on revenues and profits expected to beat guidance this year.Sales and revenues and earnings before interest, tax, depreciation and amortisation (EBITDA) are...
23 October 2015